Neurotrack is transforming the diagnosis of Alzheimer’s disease. Through a safe and non-invasive test, its technology can predict the risk of developing mild cognitive impairment and Alzheimer’s disease years before symptoms occur. Conceived at Emory University and validated by a 5-year study funded by the National Institutes of Health (NIH), it will give pharmaceutical companies better tools to recruit patients for clinical trials, leading to the development of life-saving drugs.

Neurotrack is backed by Founders Fund and Social + Capital, and was the winner of more than $7M in grants from the NIH. It was named Best Health Company at SXSW, DEMO, and participated in the Rock Health accelerator.

Palo Alto, US
13 (est)-7%

Neurotrack Locations

Palo Alto, US

Neurotrack Metrics

Neurotrack Summary

Founding Date


Total Funding

$9.59 M

Latest funding size

$6.5 M

Time since last funding

9 months


Neurotrack Company Life